Collegium Pharmaceutical, Inc. (COLL)
$21.53-2.36%Close
SELLBEAR · day 12
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $698M
- Beta
- 0.73
- P/E (TTM)
- 14.07
- Short % float
- 17.21%
- Days to cover
- 6.1
- SI change
- -2.8%
- 1W
- -1.60%
- 1M
- -5.61%
- vs SPY 1W
- -1.46%
- vs SPY 1M
- -8.12%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 40
- VALUE
- 41
- GROWTH
- 61
- GARP
- 10
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC9.6%
REV YoY-
ROE16.0%
EPS YoY-
ROA2.2%
GROSS60
OP20
NET6
[VALUATION]
P/E TTM14.07
P/E FWD3.67
SECTOR PE20.34
INDUSTRY PE19.31
P/B2.24
P/FCF-
EV/EBITDA3.01
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E275.01
ALTMAN Z-
CURR RATIO1.03
ND/EBITDA-
BETA0.73
Company news
FAQ
- What is LOPJLB’s current signal on COLL?
- LOPJLB’s latest quantitative signal on Collegium Pharmaceutical, Inc. (COLL) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is COLL in?
- Collegium Pharmaceutical, Inc. (COLL) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Collegium Pharmaceutical, Inc. (COLL) do?
- Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abu…